Sage Therapeutics (SAGE) 10-Q 6 May 16 2016 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2016	Apr. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q1
Trading Symbol	SAGE
Entity Registrant Name	Sage Therapeutics, Inc.
Entity Central Index Key	1,597,553
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		32,063,547

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 299,680	$ 186,753
Prepaid expenses and other current assets	2,926	1,738
Total current assets	302,606	188,491
Property and equipment, net	865	286
Restricted cash	39	39
Deferred offering costs		200
Total assets	303,510	189,016
Current liabilities:
Accounts payable	4,540	5,159
Accrued expenses	11,430	10,148
Total current liabilities	15,970	15,307
Other liabilities	40	14
Total liabilities	$ 16,010	$ 15,321
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; no shares issued or outstanding at March 31, 2016 and December 31, 2015, respectively
Common stock, $0.0001 par value; 120,000,000 shares authorized at March 31, 2016 and December 31, 2015, respectively; 32,038,052 and 28,823,549 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	$ 3	$ 3
Additional paid-in capital	479,380	335,032
Accumulated deficit	(191,883)	(161,340)
Total stockholders' equity	287,500	173,695
Total liabilities and stockholders' equity	$ 303,510	$ 189,016

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	120,000,000	120,000,000
Common stock, shares issued	32,038,052	28,823,549
Common stock, shares outstanding	32,038,052	28,823,549

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating expenses:
Research and development	$ 23,581	$ 12,900
General and administrative	7,133	3,997
Total operating expenses	30,714	16,897
Loss from operations	(30,714)	(16,897)
Interest income, net	175	21
Other income (expense), net	(4)	5
Net loss and comprehensive loss	$ (30,543)	$ (16,871)
Net loss per share-basic and diluted	$ (0.97)	$ (0.66)
Weighted average number of common shares used in net loss per share-basic and diluted	31,643,216	25,655,883

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (30,543)	$ (16,871)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	3,714	1,349
Non-cash licensing and consulting fees		424
Depreciation	41	22
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,189)	(134)
Accounts payable	(799)	343
Accrued expenses and other liabilities	1,341	261
Net cash used in operating activities	(27,435)	(14,606)
Cash flows from investing activities
Purchase of property and equipment	(341)	(110)
Net cash used in investing activities	(341)	(110)
Cash flows from financing activities
Proceeds from stock option exercises and employee stock purchase plan issuances	302	147
Payment of offering costs	(599)	(35)
Proceeds from public offering of common stock, net of commissions and underwriting discounts	141,000
Net cash provided by financing activities	140,703	112
Net increase (decrease) in cash and cash equivalents	112,927	(14,604)
Cash and cash equivalents at beginning of period	186,753	127,766
Cash and cash equivalents at end of period	299,680	113,162
Supplemental disclosure of non-cash investing and financing activities
Purchases of property and equipment included in accounts payable or accrued expenses	$ 279
Public offering costs included in accounts payable or accrued expenses		$ 151

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	1. Nature of Operations Sage Therapeutics, Inc. (“Sage” or the “Company”) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system (“CNS”) disorders, where there are inadequate or no approved existing therapies. The Company is targeting CNS indications where patient populations are easily identified, clinical endpoints are well-defined, and development pathways are feasible. The Company was incorporated under the laws of the state of Delaware on April 16, 2010, and commenced operations on January 19, 2011 as Sterogen Biopharma, Inc. On September 13, 2011, the Company changed its name to Sage Therapeutics, Inc. under its Second Amended and Restated Certificate of Incorporation. The Company is subject to risks and uncertainties common to companies in the biotech industry, including, but not limited to, the risks associated with developing product candidates at each stage of non-clinical and clinical development; the challenges associated with gaining regulatory approval of such product candidates; the risks associated with commercializing pharmaceutical products, if it is able to obtain regulatory approval; the potential for development by third parties of new technological innovations that may compete with the Company’s products; the dependence on key personnel; the challenges of protecting proprietary technology; the need to comply with government regulations; the high costs of drug development; and the uncertainty of being able to secure additional capital when needed to fund operations. The Company has incurred losses and negative cash flows from operations since its inception. As of March 31, 2016, the Company had an accumulated deficit of $191.9 million. From its inception through March 31, 2016, the Company received net proceeds of $454.1 million from the sales of redeemable convertible preferred stock, the issuance of convertible notes and the proceeds from its initial public offering (“IPO”) in July 2014 and follow-on underwritten public offerings in April 2015 and January 2016. Based on its current operating plans, the Company believes its cash and cash equivalents of $299.7 million as of March 31, 2016 will be sufficient to fund its anticipated level of operations and capital expenditures into the beginning of 2018.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The unaudited interim consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2015. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited interim consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of March 31, 2016, the results of its operations and comprehensive loss for the three months ended March 31, 2016 and 2015, and its cash flows for the three months ended March 31, 2016 and 2015. Such adjustments are of a normal and recurring nature. The results for the three months ended March 31, 2016 are not necessarily indicative of the results for the year ending December 31, 2016, or for any future period. Principles of Consolidation The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as disclosed in Note 2, Summary of Significant Accounting Policies, within the “Notes to Consolidated Financial Statements” accompanying its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Fair Value Measurements Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories: Level 1 — Quoted market prices in active markets for identical assets or liabilities. At March 31, 2016 and December 31, 2015, the Company’s Level 1 assets consisted of cash and money market funds totaling $299.7 million and $186.8 million, respectively. Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. At March 31, 2016 and December 31, 2015, the Company had no Level 2 assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. At March 31, 2016 and December 31, 2015, the Company had no Level 3 assets or liabilities. The Company’s financial instruments generally consist of cash equivalents, accounts payable and accrued expenses. The carrying amounts for the financial instruments reported in the balance sheets approximate their fair values at March 31, 2016 and December 31, 2015, respectively. Deferred Offering Costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as other assets until such financings are consummated. After consummation of the follow-on public offering of common stock in January 2016, $0.6 million of these costs were recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in the year ending December 31, 2018, and the Company could early adopt the standard for the year ending December 31, 2017. The Company is currently assessing the method of adoption and the impact that this new accounting guidance will have on its consolidated financial statements and footnote disclosures. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02— Leases Leases. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Accrued Expenses	3. Accrued Expenses Accrued expenses consist of the following: March 31, 2016 December 31, 2015 (in thousands) Development costs $ 9,834 $ 6,466 Employee-related expenses 980 2,718 Professional services 609 935 Other accrued expenses 7 29 $ 11,430 $ 10,148

Commitments and contingencies

Commitments and contingencies	3 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	4. Commitments and contingencies CyDex License Agreement In September 2015, the Company and CyDex Pharmaceuticals, Inc. (“CyDex”) amended and restated their existing commercial license agreement. Under the terms of the commercial license agreement as amended and restated, CyDex has granted to the Company an exclusive license to CyDex’s Captisol drug formulation technology and related intellectual property for the manufacture of pharmaceutical products incorporating the Company’s compounds known as SAGE-547 and SAGE-689, and the development and commercialization of the resulting products in the treatment, prevention or diagnosis of any disease or symptom in humans or animals other than (i) the ocular treatment of any disease or condition with a formulation, including a hormone; (ii) topical ocular treatment of inflammatory conditions; (iii) treatment and prophylaxis of fungal infections in humans; and (iv) any ocular treatment for retinal degeneration. As consideration for the inclusion of SAGE-689 in the license granted by CyDex, the Company paid to CyDex $0.1 million, which was recorded as research and development expense in 2015 in connection with the execution of the amended and restated license agreement. The Company is obligated to make milestone payments under the amended and restated license agreement with CyDex based on the achievement of clinical development and regulatory milestones in the amount of up to $0.8 million in clinical milestones and up to $3.8 million in regulatory milestones for each of the first two fields with respect to SAGE-547; up to $1.3 million in clinical milestones and up to $8.5 million in regulatory milestones for each of the third and fourth fields with respect to SAGE-547; and up to $0.8 million in clinical milestones and up to $1.8 million in regulatory milestones for one field with respect to SAGE-689. In March 2015, a clinical development milestone was met for the SAGE-547 program under the license agreement with CyDex, and accordingly, the Company recorded research and development expense for the three months ended March 31, 2015 of $0.3 million. For the three months ended March 31, 2016, the Company did not record any expense or make any milestone or royalty payments under the license agreement with CyDex. Washington University License Agreement In November 2013, the Company entered into a license agreement with Washington University whereby the Company was granted exclusive, worldwide rights to develop and commercialize a novel set of neuroactive steroids developed by Washington University. In exchange for development and commercialization rights, the Company paid an upfront, non-refundable payment of $50,000 and is required to pay an annual license maintenance fee of $15,000 on each subsequent anniversary date, until the first Phase 2 clinical trial for a licensed product is initiated. The Company is obligated to make milestone payments to Washington University based on achievement of clinical development and regulatory milestones of up to $0.7 million and $0.5 million, respectively. Additionally, the Company fulfilled its obligation to issue to Washington University 47,619 shares of common stock on December 13, 2013. The fair value of these shares totaling $0.1 million was recorded as research and development expense in 2013. The Company is obligated to pay royalties to Washington University at rates in the low single digits on net sales of licensed products covered under patent rights and royalties at rates in the low single digits on net sales of licensed products not covered under patent rights. Additionally, the Company has the right to sublicense and is required to make payments at varying percentages of sublicensing revenue received, initially in the mid-teens and descending to the mid-single digits over time. For the three months ended March 31, 2016 and 2015, the Company did not record any expense or make any milestone or royalty payments under the license agreement with Washington University. University of California License Agreements In October 2013, the Company entered into a non-exclusive license agreement with The Regents of the University of California whereby the Company was granted a non-exclusive license to certain clinical data and clinical material for use in the development and commercialization of biopharmaceutical products in the licensed field, including status epilepticus and post-partum depression. In May 2014, the license agreement was amended to add the treatment of essential tremor to the licensed field of use, materials and milestone fee provisions of the agreement. The Company paid to The Regents of the University of California clinical development milestones of up to $0.1 million and will be required to pay royalties of less than 1% on net sales for a period of fifteen years following the sale of the first product. The license will terminate on the earlier to occur of (i) 27 years after the effective date or (ii) 15 years after the last-derived product is first commercially sold. During the three months ended March 31, 2015, one clinical development milestone was met. Accordingly, the Company recorded research and development expenses and made cash payments totaling $0.1 million. In June 2015, the Company entered into an exclusive license agreement with The Regents of the University of California whereby the Company was granted an exclusive license to certain patent rights related to the use of allopregnanolone to treat various diseases. In exchange for such license, the Company paid an upfront payment of $50,000 and will make annual maintenance fees of $15,000 until the calendar year following the first sale, if any, of a licensed product. The Company is obligated to make milestone payments following the achievement of specified regulatory and sales milestones of up to $0.7 million and $2.0 million in the aggregate, respectively. Following the first sale, if any, of a licensed product, the Company is obligated to pay royalties at a low single digit percentage of net sales, if any, of licensed products, subject to specified minimum annual royalty amounts. Unless terminated by operation of law or by acts of the parties under the terms of the agreement, the license agreement will terminate when the last-to-expire patents or last-to-be abandoned patent applications expire, whichever is later. For the three months ended March 31, 2016, the Company did not record any expense or make any milestone or royalty payments under either license agreement with The Regents of the University of California. Consulting Agreement In January 2014, the Company entered into a consulting agreement with a nonemployee advisor whereby the Company is obligated to make cash payments of up to $2.0 million and to issue up to 126,984 shares of common stock upon attainment of certain clinical development and regulatory milestones. In March 2015, the second clinical development milestone for one of the programs included in the consulting agreement was met. Accordingly, the Company recorded research and development expense for the three months ended March 31, 2015 of $0.6 million, comprised of $0.2 million in cash and $0.4 million related to the issuance of 7,936 shares of the Company’s common stock, related to the achievement of this milestone. For the three months ended March 31, 2016, the Company did not record any expense or make any milestone payments under the consulting agreement with the nonemployee advisor.

Sale of Equity Securities

Sale of Equity Securities	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Sale of Equity Securities	5. Sale of Equity Securities On January 12, 2016, the Company completed the sale of 3,157,894 shares of its common stock at a price to the public of $47.50 per share, resulting in net proceeds to the Company of $140.4 million after deducting underwriting discounts and commissions and offering expenses paid by the Company.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	6. Stock-Based Compensation 2014 Stock Option Plan On July 2, 2014, the Company’s stockholders approved the 2014 Stock Option and Incentive Plan (the “2014 Stock Option Plan”), which became effective upon the completion of the IPO. The 2014 Stock Option Plan provides for the grant of restricted stock awards, incentive stock options and non-statutory stock options. The 2014 Stock Option Plan replaced the Company’s 2011 Stock Option and Grant Plan (the “2011 Stock Option Plan”). The Company will no longer grant stock options or other awards under the 2011 Stock Option Plan. Any options or awards outstanding under the 2011 Stock Option Plan remained outstanding and effective. As of March 31, 2016, the total number of shares reserved under all equity plans is 4,981,583, and the Company had 1,401,941 shares available for future issuance under such plans. The 2014 Stock Option Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s issued and outstanding shares of common stock on the immediately preceding December 31. On January 1, 2016, 1,154,653 shares of common stock, representing 4% of the Company’s issued and outstanding shares of common stock as of December 31, 2015, were added to the 2014 Stock Option Plan. Such shares are included in the equity plan totals specified in the paragraph above. Terms of restricted stock awards and stock option agreements, including vesting requirements, are determined by the Board of Directors or the Compensation Committee of the Board of Directors, subject to the provisions of the applicable stock option plan. Options and restricted stock awards granted by the Company generally vest based on the grantee’s continued service with the Company during a specified period following grant. Awards granted to employees generally vest ratably over four years, with a 25% cliff vesting at the one year anniversary for new employee awards. All awards expire in ten years. During the three months ended March 31, 2016 and 2015, the Company granted 74,039 and 497,100 options, respectively, to employees to purchase shares of common stock that contain performance-based vesting criteria, primarily related to achievement of certain clinical and regulatory development milestones related to the Company’s product candidates. Recognition of stock-based compensation expense associated with these performance-based stock options commences when the performance condition is considered probable of achievement, using management’s best estimates. During the quarter ended June 30, 2015, the achievement of one milestone was considered probable and that milestone was achieved during the quarter ended September 30, 2015. The estimated quantity of awards expected to vest was recognized by determining the cumulative expense as of June 30, 2015 and the remaining expense was recognized over the estimated service period. This milestone represents 35% of the performance-based grants that were made during 2015. The achievement of the remaining milestones was deemed to be not probable as of March 31, 2016 and therefore no expense has been recognized related to these awards in the three months ended March 31, 2016. Stock-based compensation expense recognized during the three months ended March 31, 2016 and 2015 was as follows: Three Months Ended March 31, 2016 2015 (in thousands) Research and development $ 1,611 $ 523 General and administrative 2,103 826 $ 3,714 $ 1,349 For stock option awards, the fair value is estimated at the grant date using the Black-Scholes option-pricing model, taking into account the terms and conditions upon which options are granted. The fair value of the options is amortized on a straight-line basis for awards to employees and on a graded basis for awards to non-employees over the requisite service period of the awards. The weighted average grant date fair value per share relating to outstanding stock options granted under the Company’s stock option plans during the three months ended March 31, 2016 and 2015 was $21.87 and $38.28, respectively. The fair value of each option granted to employees and nonemployee directors during the three months ended March 31, 2016 and 2015, under the Company’s stock option plans has been calculated on the date of grant using the following weighted average assumptions: Three Months Ended March 31, 2016 2015 Expected dividend yield 0% 0% Expected volatility 79.8% 93.0% Risk free interest rate 1.40% 1.46% Expected term 6.06 years 5.89 years Expected dividend yield: Risk-free interest rate: Expected volatility: Expected term (in years): Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company estimates forfeitures based on historical termination behavior. For the three months ended March 31, 2016 and 2015, forfeiture rates of 6.49% and 10.0%, respectively, were applied. For options granted to nonemployees, the expected life of the option used is ten years, which is the contractual term of each such option. All other assumptions used to calculate the grant date fair value are generally consistent with the assumptions used for options granted to employees. The table below summarizes activity related to stock options: Shares Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2015 3,002,809 $ 26.67 8.67 $ 96,479 Granted 636,975 31.80 Exercised (35,242 ) 2.10 Forfeited (24,900 ) 64.68 Outstanding as of March 31, 2016 3,579,642 $ 27.57 8.68 $ 38,036 Vested or expected to vest as of March 31, 2016 2,898,779 $ 26.48 8.62 $ 34,484 Exercisable as of March 31, 2016 924,772 $ 16.71 8.10 $ 16,206 As of March 31, 2016, the Company had unrecognized stock-based compensation expense related to its unvested service-based stock option awards of $39.0 million, which is expected to be recognized over the remaining weighted average vesting period of 3.1 years. The total fair value of shares vested for the three months ended March 31, 2016 and 2015 was $4.1 million and $0.4 million, respectively. In addition, the Company has 433,015 shares of outstanding unvested stock options that vest upon the achievement of certain performance criteria. Total unrecognized stock-based compensation expense related to those awards was $10.2 million at March 31, 2016. The intrinsic value of stock options exercised during the three months ended March 31, 2016 and 2015 was $1.4 million and $1.8 million, respectively. Restricted Stock Awards During the year ended December 31, 2013, the Company granted restricted stock awards to certain officers, employees, directors, and consultants of the Company. During the three months ended March 31, 2016 and 2015, the Company recorded $16,000 and $0.1 million, respectively, of stock-based compensation expense related to its restricted stock. The table below summarizes activity relating to restricted stock: Shares Outstanding as of December 31, 2015 42,781 Issued — Vested (18,060 ) Forfeited — Repurchased — Outstanding as of March 31, 2016 24,721 As of March 31, 2016, the Company had unrecognized stock-based compensation expense related to its unvested restricted stock awards of $19,000, which is expected to be recognized over the remaining weighted average vesting period of 0.33 years. During the three months ended March 31, 2016 and 2015, no shares of restricted stock were issued. Unvested shares are subject to repurchase by the Company, at the issuance price, upon the employee’s termination at the Company’s sole discretion. No shares were repurchased during the three months ended March 31, 2016 and 2015. 2014 Employee Stock Purchase Plan On July 2, 2014, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan, which had been previously approved by the Board of Directors. A total of 282,000 shares of common stock were initially authorized for issuance under this plan. The 2014 Employee Stock Purchase Plan became effective upon the completion of the IPO. As of March 31, 2016, 7,159 shares have been issued under this plan.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Net Loss Per Share	7. Net Loss Per Share Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2016 and 2015: Three Months Ended March 31, 2016 2015 Basic net loss per share: Numerator: Net loss (in thousands) $ (30,543 ) $ (16,871 ) Denominator: Weighted average shares of common stock outstanding—basic 31,643,216 25,655,883 Dilutive effect of shares of common stock equivalents resulting from common stock options — — Weighted average shares of common stock outstanding—diluted 31,643,216 25,655,883 Net loss per share—basic and diluted $ (0.97 ) $ (0.66 ) The following common stock equivalents outstanding as of March 31, 2016 and 2015 were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive: Three Months Ended March 31, 2016 2015 Options to purchase common stock 3,146,627 1,736,871 Restricted stock 24,721 137,184 Employee Stock Purchase Plan 3,851 — 3,175,199 1,874,055

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The Company did not record a federal or state income tax benefit for the Company’s losses for the three months ended March 31, 2016 and 2015 due to the Company’s net losses and conclusion that a valuation allowance is required.

Summary of Significant Accoun14

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited interim consolidated financial statements of the Company included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2015. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the Company’s management, the accompanying unaudited interim consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of March 31, 2016, the results of its operations and comprehensive loss for the three months ended March 31, 2016 and 2015, and its cash flows for the three months ended March 31, 2016 and 2015. Such adjustments are of a normal and recurring nature. The results for the three months ended March 31, 2016 are not necessarily indicative of the results for the year ending December 31, 2016, or for any future period.
Principles of Consolidation	Principles of Consolidation The unaudited interim consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries as disclosed in Note 2, Summary of Significant Accounting Policies, within the “Notes to Consolidated Financial Statements” accompanying its Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value Measurements	Fair Value Measurements Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the following three categories: Level 1 — Quoted market prices in active markets for identical assets or liabilities. At March 31, 2016 and December 31, 2015, the Company’s Level 1 assets consisted of cash and money market funds totaling $299.7 million and $186.8 million, respectively. Level 2 — Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. At March 31, 2016 and December 31, 2015, the Company had no Level 2 assets or liabilities. Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. At March 31, 2016 and December 31, 2015, the Company had no Level 3 assets or liabilities. The Company’s financial instruments generally consist of cash equivalents, accounts payable and accrued expenses. The carrying amounts for the financial instruments reported in the balance sheets approximate their fair values at March 31, 2016 and December 31, 2015, respectively.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued guidance that outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry specific guidance. The guidance is based on the principle that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to fulfill a contract. Entities have the option of using either a full retrospective or a modified retrospective approach for the adoption of the new standard. The guidance becomes effective for the Company in the year ending December 31, 2018, and the Company could early adopt the standard for the year ending December 31, 2017. The Company is currently assessing the method of adoption and the impact that this new accounting guidance will have on its consolidated financial statements and footnote disclosures. In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements—Going Concern In November 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes In February 2016, the FASB issued ASU 2016-02— Leases Leases. In March 2016, the FASB issued ASU No. 2016-09, Compensation - Stock Compensation
Deferred Offering Costs	Deferred Offering Costs The Company capitalizes certain legal, accounting and other third-party fees that are directly associated with in-process equity financings as other assets until such financings are consummated. After consummation of the follow-on public offering of common stock in January 2016, $0.6 million of these costs were recorded in stockholders’ equity as a reduction of additional paid-in capital generated as a result of the offering.

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2016
Text Block [Abstract]
Summary of Accrued Expenses	Accrued expenses consist of the following: March 31, 2016 December 31, 2015 (in thousands) Development costs $ 9,834 $ 6,466 Employee-related expenses 980 2,718 Professional services 609 935 Other accrued expenses 7 29 $ 11,430 $ 10,148

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Recognized Stock-Based Compensation Expense	Stock-based compensation expense recognized during the three months ended March 31, 2016 and 2015 was as follows: Three Months Ended March 31, 2016 2015 (in thousands) Research and development $ 1,611 $ 523 General and administrative 2,103 826 $ 3,714 $ 1,349
Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted	The fair value of each option granted to employees and nonemployee directors during the three months ended March 31, 2016 and 2015, under the Company’s stock option plans has been calculated on the date of grant using the following weighted average assumptions: Three Months Ended March 31, 2016 2015 Expected dividend yield 0% 0% Expected volatility 79.8% 93.0% Risk free interest rate 1.40% 1.46% Expected term 6.06 years 5.89 years
Summary of Activity Relating to Stock Options	The table below summarizes activity related to stock options: Shares Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2015 3,002,809 $ 26.67 8.67 $ 96,479 Granted 636,975 31.80 Exercised (35,242 ) 2.10 Forfeited (24,900 ) 64.68 Outstanding as of March 31, 2016 3,579,642 $ 27.57 8.68 $ 38,036 Vested or expected to vest as of March 31, 2016 2,898,779 $ 26.48 8.62 $ 34,484 Exercisable as of March 31, 2016 924,772 $ 16.71 8.10 $ 16,206
Summary of Activity Relating to Restricted Stock	The table below summarizes activity relating to restricted stock: Shares Outstanding as of December 31, 2015 42,781 Issued — Vested (18,060 ) Forfeited — Repurchased — Outstanding as of March 31, 2016 24,721

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share was calculated as follows for the three months ended March 31, 2016 and 2015: Three Months Ended March 31, 2016 2015 Basic net loss per share: Numerator: Net loss (in thousands) $ (30,543 ) $ (16,871 ) Denominator: Weighted average shares of common stock outstanding—basic 31,643,216 25,655,883 Dilutive effect of shares of common stock equivalents resulting from common stock options — — Weighted average shares of common stock outstanding—diluted 31,643,216 25,655,883 Net loss per share—basic and diluted $ (0.97 ) $ (0.66 )
Summary of Common Stock Equivalents Outstanding	The following common stock equivalents outstanding as of March 31, 2016 and 2015 were excluded from the computation of diluted net loss per share for the periods presented because including them would have been anti-dilutive: Three Months Ended March 31, 2016 2015 Options to purchase common stock 3,146,627 1,736,871 Restricted stock 24,721 137,184 Employee Stock Purchase Plan 3,851 — 3,175,199 1,874,055

Nature of Operations - Addition

Nature of Operations - Additional Information (Detail) - USD ($) $ in Thousands	72 Months Ended
	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Nature Of Operations [Line Items]
Accumulated deficit	$ (191,883)	$ (161,340)
Cash and cash equivalents	299,680	$ 186,753	$ 113,162	$ 127,766
Redeemable Convertible Preferred Stock [Member] | Convertible Notes [Member] | Initial Public Offering [Member]
Nature Of Operations [Line Items]
Net proceeds from sale of equity and notes	$ 454,100

Summary of Significant Accoun19

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 31, 2016	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Summary Of Significant Accounting Policies [Line Items]
Payment of offering costs	$ 600,000	$ 599,000	$ 35,000
Fair Value, Inputs, Level 1 [Member]
Summary Of Significant Accounting Policies [Line Items]
Assets fair value		299,700,000		$ 186,800,000
Fair Value, Inputs, Level 2 [Member]
Summary Of Significant Accounting Policies [Line Items]
Assets fair value		0		0
Liabilities fair value		0		0
Fair Value, Inputs, Level 3 [Member]
Summary Of Significant Accounting Policies [Line Items]
Assets fair value		0		0
Liabilities fair value		$ 0		$ 0

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Development costs	$ 9,834	$ 6,466
Employee-related expenses	980	2,718
Professional services	609	935
Other accrued expenses	7	29
Total accrued expenses	$ 11,430	$ 10,148

Commitments and Contingencies -

Commitments and Contingencies - CyDex License Agreement - Additional Information (Detail)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2015Milestone	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2015USD ($)
Commitments And Contingencies [Line Items]
Research and development expense		$ 23,581,000	$ 12,900,000
CyDex License Agreement [Member]
Commitments And Contingencies [Line Items]
Research and development expense				$ 100,000
CyDex License Agreement [Member] | First and Second Clinical Development Milestones [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments		800,000
CyDex License Agreement [Member] | First and Second Regulatory Milestones [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments		3,800,000
CyDex License Agreement [Member] | Third and Fourth Clinical Development Milestones [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments		1,300,000
CyDex License Agreement [Member] | Third and Fourth Regulatory Milestones [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments		8,500,000
CyDex License Agreement [Member] | Clinical Development [Member]
Commitments And Contingencies [Line Items]
Research and development expense related to milestone expense		0	$ 300,000
Milestones achieved | Milestone	1
Milestone payments		0
CyDex License Agreement [Member] | Clinical Development [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments		800,000
CyDex License Agreement [Member] | Regulatory Milestones [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments		$ 1,800,000

Commitments and Contingencies22

Commitments and Contingencies - Washington University License Agreement - Additional Information (Detail) - Washington University License Agreement [Member] - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 30, 2013	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2013
Commitments And Contingencies [Line Items]
Upfront non-refundable payment	$ 50,000
Annual license maintenance fee	15,000
Issuance of common stock, shares				47,619
Research and development expense related to milestone expense		$ 0	$ 0	$ 100,000
Milestone payments		$ 0	$ 0
Clinical Development [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments	700,000
Regulatory Milestones [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments	$ 500,000

Commitments and Contingencies23

Commitments and Contingencies - University of California License Agreements - Additional Information (Detail) - University of California License Agreements [Member]	1 Months Ended		3 Months Ended
	Jun. 30, 2015USD ($)	Oct. 31, 2013USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)Milestone
Commitments And Contingencies [Line Items]
Research and development expense related to milestone expense			$ 0
Milestone payments			$ 0
Upfront payment	$ 50,000
Annual license maintenance fee	15,000
After The Effective Date [Member]
Commitments And Contingencies [Line Items]
Licenses Expiration period, maximum			27 years
After The First Sale [Member]
Commitments And Contingencies [Line Items]
Licenses Expiration period, maximum			15 years
Regulatory Milestones [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments	700,000
Sales Milestones [Member]
Commitments And Contingencies [Line Items]
Expected milestone payments	$ 2,000,000
Clinical Development [Member]
Commitments And Contingencies [Line Items]
Milestones achieved | Milestone				1
Research and development expense related to milestone expense				$ 100,000
Milestone payments				$ 100,000
Clinical Development [Member] | Maximum [Member]
Commitments And Contingencies [Line Items]
Milestone payments		$ 100,000
Percentage of net sales paid as royalties			1.00%

Commitments and Contingencies24

Commitments and Contingencies - Consulting Agreement - Additional Information (Detail) - Consulting Agreement [Member]	1 Months Ended		3 Months Ended
	Mar. 31, 2015Milestone	Jan. 31, 2014USD ($)shares	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)shares
Commitments And Contingencies [Line Items]
Research and development expense related to milestone expense			$ 0
Milestone payments			$ 0
Clinical Development and Regulatory Milestones [Member]
Commitments And Contingencies [Line Items]
Milestone payment		$ 2,000,000
Shares of common stock for attaining milestones | shares		126,984
Second Clinical Development Milestones [Member]
Commitments And Contingencies [Line Items]
Research and development expense related to milestone expense				$ 600,000
Milestone payments				200,000
Payments for stock issued upon reaching a milestone				$ 400,000
Milestone based share compensation, shares issued | shares				7,936
Milestones achieved | Milestone	1

Sale of Equity Securities - Add

Sale of Equity Securities - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jan. 12, 2016	Mar. 31, 2016
Equity [Abstract]
Issuance of common stock, shares	3,157,894
Common stock price per share	$ 47.50
Proceeds from public offering of common stock, net of commissions and underwriting discounts and estimated offering expenses	$ 140,400	$ 141,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail)	Jan. 01, 2016shares	Jul. 02, 2014shares	Mar. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2015Milestone	Mar. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation granted under plan vest period			4 years
Share based compensation, vest period			1 year
Share based compensation, term of plan			10 years
Milestone expense | $			$ 0
Weighted average grant date fair value per share | $ / shares			$ 21.87		$ 38.28
Share option, forfeiture rate			6.49%		10.00%
Total unrecognized stock-based compensation expense | $			$ 10,200,000
Stock-based compensation expense | $			3,714,000		$ 1,349,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized stock-based compensation expense | $			$ 19,000
Weighted average period of unrecognized compensation costs			3 months 29 days
Stock-based compensation expense | $			$ 16,000		$ 100,000
Issued, Shares-Restricted stock			0		0
Stock repurchased, shares			0		0
Options to Purchase Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant			636,975
Total unrecognized stock-based compensation expense | $			$ 39,000,000
Weighted average period of unrecognized compensation costs			3 years 1 month 6 days
Total fair value of shares vested | $			$ 4,100,000		$ 400,000
Intrinsic value of options exercised | $			$ 1,400,000		$ 1,800,000
Number of shares outstanding unvested stock options			433,015
Share-based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, vesting percentage			25.00%
2014 Stock Option Plan and 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved under equity plan			4,981,583
Common stock available for issuance under 2014 Stock Option Plan			1,401,941
2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option grant			0
2014 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock available for issuance under 2014 Stock Option Plan	1,154,653
Percentage of increase on issued and outstanding shares of Common stock	4.00%
Percentage of performance based grants that were achieved						35.00%
Milestones achieved | Milestone				1
2014 Stock Option Plan [Member] | Performance Milestone [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options with performance-based criteria			74,039		497,100
2014 Stock Option Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of increase to stock option on issued and outstanding shares of Common stock		4.00%
2014 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options with performance-based criteria		282,000
Number of shares issued under the plan			7,159

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Recognized Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock-based compensation expense	$ 3,714	$ 1,349
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock-based compensation expense	1,611	523
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total Stock-based compensation expense	$ 2,103	$ 826

Stock-Based Compensation - Su28

Stock-Based Compensation - Summary of Weighted Average Assumptions Used to Compute Fair Value of Option Granted (Detail)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Expected dividend yield	0.00%	0.00%
Expected volatility	79.80%	93.00%
Risk free interest rate	1.40%	1.46%
Expected term	6 years 22 days	5 years 10 months 21 days

Stock-Based Compensation - Su29

Stock-Based Compensation - Summary of Activity Relating to Stock Options (Detail) - Options to Purchase Common Stock [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance, Stock options	3,002,809
Granted, Stock options	636,975
Exercised, Stock options	(35,242)
Forfeited, Stock options	(24,900)
Ending balance, Outstanding Shares-Stock options	3,579,642	3,002,809
Vested or expected to vest, Stock options	2,898,779
Exercisable, Stock options	924,772
Beginning balance, Weighted Average Exercise Price-Stock options	$ 26.67
Granted, Weighted Average Exercise Price-Stock options	31.80
Exercised, Weighted Average Exercise Price-Stock options	2.10
Forfeited, Weighted Average Exercise Price-Stock options	64.68
Ending balance, Outstanding Weighted Average Exercise Price-Stock options	27.57	$ 26.67
Vested or expected to vest, Weighted Average Exercise Price-Stock options	26.48
Exercisable, Weighted Average Exercise Price-Stock options	$ 16.71
Outstanding, Weighted Average Remaining Life-Stock options	8 years 8 months 5 days	8 years 8 months 1 day
Vested or expected to vest, Weighted Average Remaining Life-Stock options	8 years 7 months 13 days
Exercisable, Weighted Average Remaining Life-Stock options	8 years 1 month 6 days
Outstanding, Aggregate Intrinsic Value-Stock options	$ 38,036	$ 96,479
Vested or expected to vest, Aggregate Intrinsic Value-Stock options	34,484
Exercisable, Aggregate Intrinsic Value-Stock options	$ 16,206

Stock-Based Compensation - Su30

Stock-Based Compensation - Summary of Activity Relating to Restricted Stock (Detail) - Restricted Stock [Member] - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Shares at beginning balance-Restricted stock	42,781
Issued, Shares-Restricted stock	0	0
Vested, Shares-Restricted stock	(18,060)
Forfeited, Shares-Restricted stock	0
Repurchased, Shares-Restricted stock	0	0
Outstanding, Shares at ending balance-Restricted stock	24,721

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Numerator:
Net loss	$ (30,543)	$ (16,871)
Denominator:
Weighted average shares of common stock outstanding-basic	31,643,216	25,655,883
Dilutive effect of shares of common stock equivalents resulting from common stock options	0	0
Weighted average shares of common stock outstanding-diluted	31,643,216	25,655,883
Net loss per share-basic and diluted	$ (0.97)	$ (0.66)

Net Loss Per Share - Summary 32

Net Loss Per Share - Summary of Common Stock Equivalents Outstanding (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	3,175,199	1,874,055
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	3,146,627	1,736,871
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	24,721	137,184
Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	3,851

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
State income tax benefit	$ 0	$ 0
Federal income tax benefit	$ 0	$ 0